EAU 2020: The Real Effect of Prostate Cancer Treatment: EUPROMS First-Ever Prostate Patient-Driven Quality of Life Study
Presented by André Deschamps, MD
(UroToday.com) André Deschamps, MD, presented a study assessing the quality of life of patients after being treated for prostate cancer. The study involved a 20-minute online survey intended for patients with prostate cancer who received treatment in Europe. It is an observational one-arm study, aiming to examine the quality of life of prostate cancer patients in Europe.
Read More
SUO - AUA Summer Webcast: Supportive and Palliative Care for Urologists
Presented by Elizabeth Wulff-Burchfield, MD
(UroToday.com) Elizabeth Wulff-Burchfield, MD, is a medical oncologist specializing in palliative care. At the 2020 Society of Urologic Oncology Virtual Webcast, she discussed supportive and palliative care for urologists.
Read More
SUO 2019: Implementation of Standard Opioid Prescribing Schedules Following Urologic Surgeries Reduces Opioid Prescriptions Without Change in Patient Reported Outcomes
Presented by Kathryn Hacker Gessner, MD, Ph.D.
Washington, DC (UroToday.com) There is an increasing recognition that postoperative opioid prescriptions are contributing to the opioid crisis in the United States. This is in part due to the diversion of excess opioid medications,
Read More
ESMO 2019: Patient-Reported Outcomes From TITAN in Patients with Metastatic Castration-Sensitive Prostate Cancer
Presented by Neeraj Agarwal, MD
Barcelona, Spain (UroToday.com) Androgen deprivation therapy (ADT) has long been considered the standard of care for patients with metastatic prostate cancer, however recent studies have shown improved survival outcomes by adding additional agents.
Read More
ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma
Presented by Sumanta K. Pal, MD
Chicago, IL (UroToday.com) The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi), additional TKI’s (cabozantinib),
Read More